Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Brief Summary: A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum based chemotherapy.


Options:
A: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets
B: Arm Label: Arm I (paclitaxel, docetaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Arm Label: Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Arm Label: Arm III (gemcitabine hydrochloride, carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Gemcitabine Hydrochloride, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment | Arm Label: Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab), Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (paclitaxel, docetaxel, carboplatin), Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab), Arm III (gemcitabine hydrochloride, carboplatin), Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm I (paclitaxel, docetaxel, carboplatin), Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm III (gemcitabine hydrochloride, carboplatin), Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel, docetaxel, carboplatin), Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab), Arm III (gemcitabine hydrochloride, carboplatin), Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel, docetaxel, carboplatin), Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (paclitaxel, docetaxel, carboplatin), Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab), Arm III (gemcitabine hydrochloride, carboplatin), Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin)
C: Arm Label: Bevacizumab + paclitaxel + carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab + paclitaxel + carboplatin | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Bevacizumab + paclitaxel + carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Bevacizumab + paclitaxel + carboplatin
D: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer

Answer: A